NCT Number: NCT02769663
Cognitive Complaints in Obstructive Sleep Apnea
The study assesses cognitive complaints in newly diagnosed patients with obstructive sleep apnea with no medical-comorbity affecting cognition. Cognitive complaints will be compared to healthy controls matched on age, sex and educational level. Factors related to cognitive complaints will also be assessed, including anxiety and depressive symptoms, complaints of fatigue and sleepiness, quality of life, psychological coping strategies and objective measures of cognition. Patients starting treatment for sleep apnea (continuous positive airway pressure or mandibular repositioning device) will be reassessed on all measures after 6 months of treatment to study the impact of treatment as usual on cognitive complaints and its related factors.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Observational
Primary location
VieCuri Medisch Centrum, Venlo, Limburg, Netherlands
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- native Dutch speaker
- estimated verbal-IQ of ≥80
Exclusion criteria
- other sleep disorder than obstructive sleep apnea
- substance or alcohol abuse (e.g. no more than three units of alcohol per day for males and no more than two units of alcohol per day for females
- diagnosis of a psychiatric disorder
- use of medication effecting cognition
- neurological disease, diabetes mellitus, hypo- or hyperthyroidism or lung disease (as checked by verbal report and medical records)
Treatment and study plan
Primary outcomes
-
Cognitive Failure Questionnaire (CFQ)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
Questionnaire assessing cognitive complaints
-
Behavior Rating Inventory of Executive Function Adult version (BRIEF-A)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
Questionnaire assessing cognitive complaints
Secondary outcomes
-
Hospital Anxiety and Depression Scale (HADS)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
questionnaire assessing anxiety and depressive symptoms
-
Fatigue Assessment Scale (FAS)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
questionnaire assessing fatigue
-
Epworth Sleepiness Scale (ESS)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
questionnaire assessing sleepiness
-
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
questionnaire screening for sleep disorders and assessing sleep quality
-
Sleep diary
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
subjective measure for sleep quality
-
World Health Organisation Quality of Life Questionnaire BREF (WHOQOL-bref)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
questionnaire measuring quality of life
-
Utrechtse Coping Lijst (UCL)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
questionnaire measuring psychological coping strategies
-
Dutch reading tests for adults (NLV)
Time frame: Assessed at inclusion of study.
cognitive test for verbal intelligence
-
Central Nervous System Vital Signs Symbol Digit Coding (CNS-VS-SDC)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for attention
-
Central Nervous System Vital Signs Continuous Performance Test (CNS-VS-CPT)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for attention
-
Central Nervous System Vital Signs Stroop Test (CNS-VS-ST)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for attention/executive function
-
Central Nervous System Vital Signs Shifting Attention Test (CNS-VS-SAT)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for attention/executive function
-
Rey Auditory Verbal Learning Test (RAVLT)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for memory
-
Wechsler Adult Intelligence Scale III - Digit Span (WAIS-III-DS)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for attention/executive function
-
Trail Making Test (TMT)
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for attention/executive function
-
Semantic Fluency
Time frame: Assessed at inclusion of study and, if treatment is started, after 6 months of treatment.
cognitive test for executive function
Sponsors and collaborators
Lead sponsor
VieCuri Medical Centre
Other
Collaborators
- Reinier de Graaf Groep
- Tilburg University
Registry information
Important dates
- Study start
- 2012
- Primary completion
- 2018
- Study completion
- 2019
- First posted
- May 11, 2016
- Registry last updated
- Jul 14, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
NCT02813434
Brain Diseases, Central Nervous System Diseases
Amiens, France
View Trial DetailsImpact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
NCT03061006
Brain Diseases, Central Nervous System Diseases
Murray, Utah, United States
View Trial DetailsDual-Task Improvement in Parkinson's Via rTMS
NCT07310238
Basal Ganglia Diseases, Brain Diseases
Gaziantep, Turkey (Türkiye)
View Trial DetailsNeuropsychological Outcome After Cardiac Arrest
NCT03543371
Brain Diseases, Brain Ischemia
Aarhus, Denmark
View Trial Details